StockCIK 1880438
AN2 Therapeutics, Inc. (ANTX): Insider Trades and Fund Holdings
In the past 12 months, AN2 Therapeutics, Inc. insiders reported 1 open-market purchase worth $12K and 5 sales worth $318K; 4 of the sales were reported as made under a 10b5-1 trading plan.
1Insider buys, 12 months
$12KBought by insiders, 12 months
$318KSold by insiders, 12 months
1Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 11, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 11 | Robin Shane ReadnourDirector | ▼ SELL10b5-1 | $7K |
| Sep 8 | Robin Shane ReadnourDirector | ▼ SELL10b5-1 | $60K |
| Sep 8 | Robin Shane ReadnourDirector | ▼ SELL10b5-1 | $37K |
| Sep 4 | Sarah Joanne WilliamsPrincipal Accounting Officer | ▼ SELL | $2K |
| Sep 2 | Margaret M. FitzpatrickDirector | ▲ BUY | $12K |
| Aug 19 | Robin Shane ReadnourDirector | ▼ SELL10b5-1 | $213K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Robin Shane Readnour | Director | 0 | $0 | 4 | $317K |
| Sarah Joanne Williams | Principal Accounting Officer | 0 | $0 | 1 | $2K |
| Margaret M. Fitzpatrick | Director | 1 | $12K | 0 | $0 |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report ANTX
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 129,700 | $628K | ▼ −34.8% |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →